Tissue plasminogen activator (t-PA) promotes neutrophil degranulation and MMP-9 release

Journal of Leukocyte Biology

Volumn 84, Issue 1, 2008, Pages 207-214

  Cuadrado, Eloy ^a   Ortega, Laura ^a   Hernández Guillamon, Mar ^a   Penalba, Anna ^a   Fernández Cadenas, Israel ^a   Rosell, Anna ^a,b,c   Montaner, Joan ^a,d  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

Hemorrhage; Plasmin; Stroke; TIMP 2; TIRF

Indexed keywords

ALTEPLASE; GELATINASE B; NEUTROPHIL COLLAGENASE; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DEGRANULATION; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; MALE; NEUTROPHIL; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN SECRETION; STROKE; WESTERN BLOTTING; ZYMOGRAPHY;

ADULT; CELL DEATH; CELL DEGRANULATION; CELL MEMBRANE; FEMALE; HUMANS; MALE; MATRIX METALLOPROTEINASE 8; MATRIX METALLOPROTEINASE 9; MICROSCOPY, FLUORESCENCE; N-FORMYLMETHIONINE LEUCYL-PHENYLALANINE; NEUTROPHIL ACTIVATION; NEUTROPHILS; TISSUE INHIBITOR OF METALLOPROTEINASE-2; TISSUE PLASMINOGEN ACTIVATOR;

EID: 46949106173     PISSN: 07415400     EISSN: None     Source Type: Journal    
DOI: 10.1189/jlb.0907606     Document Type: Article

References (37)

1. Rosenberg, G. A., Navratil, M., Barone, F., Feuerstein, G. (1996) Proteolytic cascade enzymes increase in focal cerebral ischemia in rat. J. Cereb. Blood Flow Metab. 16, 360-366.
2. Montaner, J., Alvarez-Sabín, J., Molina, C., Anglés, A., Abilleira, S., Arenillas, J., González, M. A., Monasterio, J. (2001) Matrix metalloproteinase expression after human cardioembolic stroke: temporal profile and relation to neurological impairment. Stroke 32, 1759-1766.
3. Clark, A. W., Krekoski, C. A., Bou, S-S., Chapman, K. R., Edwards, D. R. (1997) Increased gelatinase A (MMP-2) and gelatinase B (MMP-9) activities in human brain after focal ischemia. Neurosci. Lett. 238, 53-56.
4. Anthony, D. C., Ferguson, B., Matyzak, M. K., Miler, K. M., Esiri, M. M., Perry, V. H. (1997) Differential matrix metalloproteinases expression in cases of multiple sclerosis and stroke. Neuropathol. Appl. Neurobiol. 23, 406-415.
5. Rosell, A., Ortega-Aznar, A., Alvarez-Sabin, J., Fernandez-Cadenas, I., Ribo, M., Molina, C. A., Lo, E. H., Montaner, J. (2006) Increased brain expression of matrix metalloproteinase-9 after ischemic and hemorrhagic human stroke. Stroke 37, 1399-1406.
6. Justicia, C., Panes, J., Sole, S., Cervera, A., Deulofeu, R., Chamorro, A., Planas, A. M. (2003) Neutrophil infiltration increases matrix metalloproteinase-9 in the ischemic brain after occlusion/reperfusion of the middle cerebral artery in rats. J. Cereb. Blood Flow Metab. 23, 1430-1440.
7. Gidday, J. M., Gasche, Y. G., Copin, J. C., Shah, A. R., Perez, R. S., Shapiro, S. D., Chan, P. H., Park, T. S. (2005) Leukocyte-derived matrix metalloproteinase-9 mediates blood-brain barrier breakdown and is proinflammatory after transient focal cerebral ischemia. Am. J. Physiol. Heart Circ. Physiol. 289, H558-H568.
8. Agrawal, S., Anderson, P., Durbeej, M., van Rooijen, N., Ivars, F., Opdenakker, G., Sorokin, L. M. (2006) Dystroglycan is selectively cleaved at the parenchymal basement membrane at sites of leukocyte extravasation in experimental autoimmune encephalomyelitis. J. Exp. Med. 203, 1007-1019.
9. Wang, X., Tsuji, K., Lee, S. R., Ning, M., Furie, K. L., Buchan, A. M., Lo, E. H. (2004) Mechanisms of hemorrhagic transformation after tissue plasminogen activator reperfusion therapy for ischemic stroke. Stroke 35, 2726-2730.
10. Wahlgren, N., Ahmed, N., Davalos, A., Ford, G. A., Grond, M., Hacke, W., Hennerici, M. G., Kaste, M., Kuelkens, S., Larrue, V., Lees, K. R., Roine, R. O., Soinne, L., Toni, D., Vanhooren, G., SITS-MOST Investigators (2007) Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study. Lancet 369, 275-282.
11. Montaner, J., Alvarez-Sabin, J., Molina, C. A., Angles, A., Abilleira, S., Arenillas, J., Monasterio, J. (2001) Matrix metalloproteinase expression is related to hemorrhagic transformation after cardioembolic stroke. Stroke 32, 2762-2767.
12. Ning, M., Furie, K. L., Koroshetz, W. J., Lee, H., Barron, M., Lederer, M., Wang, X., Zhu, M., Sorensen, A. G., Lo, E. H., Kelly, P. J. (2006) Association between tPA therapy and raised early matrix metalloproteinase-9 in acute stroke. Neurology 66, 1550-1555.
13. Asahi, M., Asahi, K., Jung, J. C., del Zoppo, G. J., Fini, M. E., Lo, E. H. (2000) Role for matrix metalloproteinase 9 after focal cerebral ischemia: effects of gene knockout and enzyme inhibition with BB-94. J. Cereb. Blood Flow Metab. 20, 1681-1689.
14. Sumii, T., Lo, E. H. (2002) Involvement of matrix metalloproteinase in thrombolysis-associated hemorrhagic transformation after embolic focal ischemia in rats. Stroke 33, 831-836.
15. Rosell, A., Cuadrado, E., Ortega-Aznar, A., Hernández-Guillamon, M., Lo, E. H., Montaner, J. (2007) MMP-9-positive neutrophil infiltration is strongly associated to BBB breakdown and basal lamina type IV collagen degradation during hemorrhagic transformation after human ischemic stroke. Stroke, in press.
16. Schleimer, R. P., Rutledge, B. K. (1986) Cultured human vascular endothelial cells acquire adhesiveness for neutrophils after stimulation with interleukin 1, endotoxin, and tumor-promoting phorbol diesters. J. Immunol. 136, 649-654.
17. Nanda, A., Brumell, J. H., Nordstrom, T., Kjeldsen, L., Sengelov, H., Borregaard, N., Rotstein, O. D., Grinstein, S. (1996) Activation of proton pumping in human neutrophils occurs by exocytosis of vesicles bearing vacuolar-type H+-ATPases. J. Biol. Chem. 271, 15963-15970.
18. Yan, L., Borregaard, N., Kjeldsen, L., Moses, M. A. (2001) The high molecular weight urinary matrix metalloproteinase (MMP) activity is a complex of gelatinase B/MMP-9 and neutrophil gelatinase-associated lipocalin (NGAL). Modulation of MMP-9 activity by NGAL. J. Biol. Chem. 276, 37258-37265.
19. Crossley, L. J. (2003) Neutrophil activation by fMLP regulates FOXO (forkhead) transcription factors by multiple pathways, one of which includes the binding of FOXO to the survival factor Mcl-1. J. Leukoc. Biol. 74, 583-592.
20. Ernens, I., Rouy, D., Velot, E., Devaux, Y., Wagner, D. R. (2006) Adenosine inhibits matrix metalloproteinase-9 secretion by neutrophils: implication of A2a receptor and cAMP/PKA/Ca2+ pathway. Circ. Res. 99, 590-597.
21. Nagamatsu, S., Ohara-Imaizumi, M., Nakamichi, Y., Kikuta, T., Nishiwaki, C. (2006) Imaging docking and fusion of insulin granules induced by antidiabetes agents: sulfonylurea and glinide drugs preferentially mediate the fusion of newcomer, but not previously docked, insulin granules. Diabetes 55, 2819-2825.
22. Faurschou, M., Borregaard, N. (2003) Neutrophil granules and secretory vesicles in inflammation. Microbes Infect. 5, 1317-1327.
23. Borregaard, N., Cowland, J. B. (1997) Granules of the human neutrophilic polymorphonuclear leukocyte. Blood 89, 3503-3521.
24. Lominadze, G., Powell, D. W., Luerman, G. C., Link, A. J., Ward, R. A., McLeish, K. R. (2005) Proteomic analysis of human neutrophil granules. Mol. Cell. Proteomics 4, 1503-1521.
25. Tsuji, K., Aoki, T., Tejima, E., Arai, K., Lee, S. R., Atochin, D. N., Huang, P. L., Wang, X., Montaner, J., Lo, E. H. (2005) Tissue plasminogen activator promotes matrix metalloproteinase-9 upregulation after focal cerebral ischemia. Stroke 36, 1954-1959.
26. Montaner, J., Molina, C. A., Monasterio, J., Abilleira, S., Arenillas, J. F., Ribo, M., Quintana, M., Alvarez-Sabin, J. (2003) Matrix metalloproteinase-9 pretreatment level predicts intracranial hemorrhagic complications after thrombolysis in human stroke. Circulation 107, 598-603.
27. Strbian, D., Karjalainen-Lindsberg, M. L., Kovanen, P. T., Tatlisumak, T., Lindsberg, P. J. (2007) Mast cell stabilization reduces hemorrhage formation and mortality after administration of thrombolytics in experimental ischemic stroke. Circulation 116, 411-418.
28. Weinstein, M., Restrepo, R., Chait, P. G., Connolly, B., Temple, M., Macarthur, C. (2004) Effectiveness and safety of tissue plasminogen activator in the management of complicated parapneumonic effusions. Pediatrics 113, e182-e185.
29. Owen, C. A., Hu, Z., Barrick, B., Shapiro, S. D. (2003) Inducible expression of tissue inhibitor of metalloproteinases-resistant matrix metalloproteinase-9 on the cell surface of neutrophils. Am. J. Respir. Cell Mol. Biol. 29, 283-294.
30. Pugin, J., Widmer, M. C., Kossodo, S., Liang, C. M., Preas, H. L., Suffredini, A. F. (1999) Human neutrophils secrete gelatinase B in vitro and in vivo in response to endotoxin and proinflamatory mediators. Am. J. Respir. Cell Mol. Biol. 20, 458-464.
31. Opdenakker, G., Van den Steen, P. E., Dubois, B., Nelissen, I., Van Coillie, E., Masure, S., Proost, P., Van Damme, J. (2001) Gelatinase B functions as regulator and effector in leukocyte biology. J. Leukoc. Biol. 69, 851-859.
32. Chakrabarti, S., Zee, J. M., Patel, K. D. (2006) Regulation of matrix metalloproteinase-9 (MMP-9) in TNF-stimulated neutrophils: novel pathways for tertiary granule release. J. Leukoc. Biol. 79, 214-222.
33. Van Lint, P., Libert, C. (2006) Matrix metalloproteinase-8: cleavage can be decisive. Cytokine Growth Factor Rev. 17, 217-223.
34. Zebrowska, A., Narbutt, J., Sysa-Jedrzejowka, A., Kobos, J., Waszcybowska, E. (2005) The imbalance between metalloproteinases and their tissue inhibitors is involved in the pathogenesis of dermatitis herpetiformis. Mediators Inflamm. 2005, 373-379.
35. Schruefer, R., Sulyok, S., Schymeinsky, J., Peters, T., Scharffetter-Kochanek, K., Walzoq, B. (2006) The proangiogenic capacity of polymorphonuclear neutrophils delineated by microarray technique and by measurement of neovascularization in wounded skin of CD-18-deficient mice. J. Vasc. Res. 43, 1-11.
36. Roelofs, J. J., Rouschop, K. M., Leemans, J. C., Claessen, N., de Boer, A. M., Frederiks, W. M., Lijnen, H. R., Weening, J. J., Florquin, S. (2006) Tissue-type plasminogen activator modulates inflammatory responses and renal function in ischemia reperfusion injury. J. Am. Soc. Nephrol. 17, 131-140.
37. Renckens, R., Roelofs, J. J., Florquin, S., de Vos, A. F., Pater, J. M., Lijnen, H. R., Carmeliet, P., van't Veer, C., van der Poll, T. (2006) Endogenous tissue-type plasminogen activator is protective during Escherichia coli-induced abdominal sepsis in mice. J. Immunol. 177, 1189-1196.